Twin Health – the creators of the Whole Body Digital Twin service for reversing, improving, and preventing chronic metabolic diseases – recently announced it secured $50 million in funding to continue expanding its groundbreaking technology and clinical service solutions for more members across the United States.
Twin Health has introduced the Whole Body Digital Twin, a dynamic model of each individual’s unique metabolism – powered by AI – that is built from thousands of data points collected daily via wearable sensors, clinical lab parameters, and self-reported preferences. With an easy-to-use app, the Whole Body Digital Twin provides members and their Twin Health licensed clinical care team individualized, precise, and timely guidance across nutrition, sleep, activity, and stress. Twin Health’s chronic metabolic disease solution is available now through Twin Health’s employer and health plan partners.
Chronic metabolic disease – which affects 60% of Americans – is a growing concern globally. And the global prevalence of Metabolic Syndrome is estimated as 20-25%. Worldwide, 415 million people are living with type 2 diabetes, and more than 500 million are expected by 2040, according to the CDC.
Chronic metabolic diseases like type 2 diabetes, obesity, fatty liver, and dyslipidemia can start as an individual’s metabolism breaks down over time. And medical research has shown that each person’s metabolism functions uniquely, presenting significant challenges to healthcare providers’ understanding and ability to customize personalized treatment.
Twin Health’s patented Whole Body Digital Twin addresses this complexity using cutting-edge technology and advanced medical science to deliver personalized, precise, and timely insights with easy-to-follow recommendations to address the root cause.
Twin Health expanded its reach with strategic partners in the employer and health plan domains, covering over 4 million lives. And notable achievements include completing the world’s first randomized controlled trial (RCT) for reversing chronic metabolic disease using digital twin technology.
The one-year results (recently published in the American Association of Clinical Endocrinology) showed a significant reduction in HbA1c in the intervention group (2.9% reduction from 9.0 to 6.1) and a significantly higher elimination of diabetes medications (elimination of 94% of type 2 diabetes medications in the intervention group). The study demonstrated an average of 16.3 lbs in weight loss, and 64% of members witnessed a normalization of their baseline non-alcoholic fatty liver disease (NAFLD). The RCT continues into its 3rd year with sustained health outcomes.
Temasek led the funding round. Existing investors ICONIQ Growth, Sofina, Peak XV, and Helena also participated in this financing round.
KEY QUOTES:
“The funding will help propel our strategy to scale the availability of our transformative technology and the way it’s deployed to even more health plans and employer partners, achieving lower costs, better outcomes, and higher satisfaction among their members and employees.”
— Jahangir Mohammed, Founder and CEO of Twin Health
“Today, a large and growing number of people around the world are suffering from chronic metabolic disease including type-2 diabetes, pre-diabetes, and obesity. Twin’s innovative approach combines advanced technology, machine learning, and compassionate care to change the lives of these people. It allows people to take control of their health and reverse these metabolic diseases, including type-2 diabetes, while also eliminating the need for high-cost medications. Twin is delivering on its promise of happier and healthier people with significant cost savings to households and employer healthcare plans. A step forward for humanity.”
— Kevin Johnson, former CEO of Starbucks, who is on Twin Health’s board of directors
